生物信息科学家(遗传咨询方向)
广州燃石医学检验所有限公司
- 公司规模:1000-5000人
- 公司性质:民营公司
- 公司行业:制药/生物工程
职位信息
- 发布日期:2017-07-10
- 工作地点:上海-闵行区
- 招聘人数:若干人
- 学历要求:硕士
- 职位月薪:1.2-2.2万/月
- 职位类别:生物工程/生物制药
职位描述
职位描述:
主要职责:
-肿瘤基因检测报告的医学和生物学意义解读及遗传咨询
-与部门同事协作维护及优化突变注释流程
-基因组突变数据库维护
任职要求:
-较好的文献检索和阅读能力
-善于沟通,善于化繁为简
-良好的学习和逻辑分析能力
-勤奋认真,团队合作
-研究生及以上学历,博士优先
-生物信息学或分子遗传学相关专业
-肿瘤学、遗传学背景优先
-熟悉ACMG指南和NGS数据分析优先
-熟悉MySQL等数据库语言优先
-熟悉Linux, R, perl或python等语言优先
举报
分享
主要职责:
-肿瘤基因检测报告的医学和生物学意义解读及遗传咨询
-与部门同事协作维护及优化突变注释流程
-基因组突变数据库维护
任职要求:
-较好的文献检索和阅读能力
-善于沟通,善于化繁为简
-良好的学习和逻辑分析能力
-勤奋认真,团队合作
-研究生及以上学历,博士优先
-生物信息学或分子遗传学相关专业
-肿瘤学、遗传学背景优先
-熟悉ACMG指南和NGS数据分析优先
-熟悉MySQL等数据库语言优先
-熟悉Linux, R, perl或python等语言优先
职能类别: 生物工程/生物制药
公司介绍
关于燃石医学
燃石医学(纳斯达克代码:BNR)成立于2014年,公司使命为“用科学守护生命之光”,专注于为肿瘤精准医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)基于NGS的肿瘤患病人群检测,6年间,燃石累计检测样本超过18.5万例,在中国市场份额领跑行业;2)基于NGS的癌症早检,目前已经进入临床验证阶段。
燃石医学于2018年7月率先获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒,在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核,以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
燃石医学(纳斯达克代码:BNR)成立于2014年,公司使命为“用科学守护生命之光”,专注于为肿瘤精准医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1)基于NGS的肿瘤患病人群检测,6年间,燃石累计检测样本超过18.5万例,在中国市场份额领跑行业;2)基于NGS的癌症早检,目前已经进入临床验证阶段。
燃石医学于2018年7月率先获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒,在体外诊断领域具有里程碑式意义。实验室获得广东省临检中心颁发的 “高通量测序实验室”技术审核,以及得美国CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准医疗领域的发展。
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
联系方式
- Email:simin.huang@brbiotech.com
- 公司地址:广州国际生物岛星岛环北路5号(燃石医学)
- 电话:17710099363